[go: up one dir, main page]

PE20231656A1 - Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos - Google Patents

Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos

Info

Publication number
PE20231656A1
PE20231656A1 PE2023001523A PE2023001523A PE20231656A1 PE 20231656 A1 PE20231656 A1 PE 20231656A1 PE 2023001523 A PE2023001523 A PE 2023001523A PE 2023001523 A PE2023001523 A PE 2023001523A PE 20231656 A1 PE20231656 A1 PE 20231656A1
Authority
PE
Peru
Prior art keywords
crystalline forms
deoxycytidine kinase
kinase inhibitor
dck
methods
Prior art date
Application number
PE2023001523A
Other languages
English (en)
Inventor
David Litzinger
Kenneth A Schultz
Original Assignee
Trethera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trethera Corp filed Critical Trethera Corp
Publication of PE20231656A1 publication Critical patent/PE20231656A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En el presente documento se describen formas cristalinas de compuestos que son inhibidores de la desoxicitidina cinasa (dCK), metodos para preparar tales formas cristalinas, composiciones farmaceuticas y medicamentos que comprenden tales formas cristalinas y metodos para usar tales formas cristalinas en el tratamiento de afecciones, enfermedades o trastornos que se beneficiaria de la modulacion de la actividad de la desoxicitidina quinasa (dCK).
PE2023001523A 2020-11-02 2021-11-01 Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos PE20231656A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108803P 2020-11-02 2020-11-02
US202163190107P 2021-05-18 2021-05-18
PCT/US2021/057584 WO2022094409A1 (en) 2020-11-02 2021-11-01 Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
PE20231656A1 true PE20231656A1 (es) 2023-10-17

Family

ID=81380719

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001523A PE20231656A1 (es) 2020-11-02 2021-11-01 Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos

Country Status (11)

Country Link
US (3) US20220133735A1 (es)
EP (1) EP4237421A4 (es)
JP (1) JP2023548605A (es)
KR (1) KR20230129384A (es)
AU (1) AU2021368138A1 (es)
CA (1) CA3196694A1 (es)
CL (1) CL2023001230A1 (es)
MX (1) MX2023005056A (es)
PE (1) PE20231656A1 (es)
TW (1) TW202233613A (es)
WO (1) WO2022094409A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021368138A1 (en) 2020-11-02 2023-06-22 Trethera Corporation Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
NZ267842A (en) 1993-05-28 1997-09-22 Baylor College Medicine Apparatus for measuring molecular mass (by mass spectrometry) in which the sample is ionised on the sample holder and desorbed therefrom by laser pulses
GB9717926D0 (en) 1997-08-22 1997-10-29 Micromass Ltd Methods and apparatus for tandem mass spectrometry
US6040575A (en) 1998-01-23 2000-03-21 Analytica Of Branford, Inc. Mass spectrometry from surfaces
GB0031103D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1480640B1 (en) 2002-02-25 2007-08-15 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
DE60324898D1 (de) 2002-02-25 2009-01-08 Lilly Co Eli Modulatoren von peroxisome proliferator-aktivierten rezeptoren
JP2006514069A (ja) 2003-01-06 2006-04-27 イーライ リリー アンド カンパニー Ｐｐａｒ調節因子としての融合複素環式誘導体
CN101277940A (zh) 2005-10-06 2008-10-01 塞诺菲-安万特股份有限公司 4-氧基-n-[1,3,4]-噻二唑-2-基-苯磺酰胺、它们的制备方法及它们作为药物的用途
US8552174B2 (en) 2005-10-31 2013-10-08 Agilent Technologies, Inc. Solutions, methods, and processes for deprotection of polynucleotides
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
US8093245B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. 4-amino-1H-pyrimidin-2-one based compounds, compositions comprising them and methods of their use
US8093246B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
KR101546080B1 (ko) 2007-09-19 2015-08-20 더 리전츠 오브 더 유니버시티 오브 캘리포니아 면역 활성화 및 선택된 암의 영상화를 위한 양성자방출 단층촬영 프로브
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
US9688673B2 (en) * 2011-03-08 2017-06-27 The Regents Of The University Of California Deoxycytidine kinase binding compounds
CN103957917A (zh) 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
BR112016003019A2 (pt) 2013-08-13 2017-09-12 Univ Illinois composto, composição farmacêutica, método para tratar câncer em um sujeito com necessidade do mesmo, e método para inibir uma desoxicitidina quinase
WO2016130562A2 (en) 2015-02-09 2016-08-18 The Regents Of The University Of California Metabolic analysis of the nucleotide de novo and salvage pathways
US20190000850A1 (en) 2015-02-09 2019-01-03 The Regents Of The University Of California Combination cancer therapy
CA3010723A1 (en) * 2016-01-08 2017-07-13 The Regents Of The University Of California Deoxycytidine kinase binding compounds
SG11201809822SA (en) 2016-05-25 2018-12-28 Singapore Health Serv Pte Ltd Atropine-containing aqueous composition
MX2019014875A (es) * 2017-06-21 2021-01-29 SHY Therapeutics LLC Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
EP3755699A1 (en) * 2018-02-21 2020-12-30 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
AU2021368138A1 (en) 2020-11-02 2023-06-22 Trethera Corporation Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof

Also Published As

Publication number Publication date
US20250049808A1 (en) 2025-02-13
CL2023001230A1 (es) 2023-11-17
EP4237421A1 (en) 2023-09-06
US20220135555A1 (en) 2022-05-05
MX2023005056A (es) 2023-07-24
WO2022094409A1 (en) 2022-05-05
TW202233613A (zh) 2022-09-01
JP2023548605A (ja) 2023-11-17
KR20230129384A (ko) 2023-09-08
US20220133735A1 (en) 2022-05-05
AU2021368138A1 (en) 2023-06-22
CA3196694A1 (en) 2022-05-05
EP4237421A4 (en) 2024-11-06
US11446307B2 (en) 2022-09-20

Similar Documents

Publication Publication Date Title
CO2020013601A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
CL2022000998A1 (es) Inhibidores de las cinasas raf
DOP2024000081A (es) Inhibidores de moléculas pequeñas de la proteasa específica de ubiquitina 1 (usp1) y sus usos
DOP2009000181A (es) Compuestos inhibidores de mek composiciones farmaceuticas que lo comprende y usos del mismo para la fabricacion de un medicamento
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
CO2019011708A2 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR111233A1 (es) Inhibidores de tyk2, usos y métodos para la producción de los mismos
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
MX381890B (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
BR112023016590A2 (pt) Inibidores de tyk2 e seus usos
CL2022001887A1 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
MX2022002532A (es) Métodos para generar y aislar neuronas de dopamina del mesencéfalo.
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
MX2022000646A (es) Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms).
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
NZ752587A (en) Lsd1 inhibitors and medical uses thereof
CO2019002517A2 (es) Inhibidores de dopamina–β–hidroxilasa
CO2024009144A2 (es) Inhibidores de cinasa met
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
MX2021012749A (es) Inhibidor selectivo de la jak1 cinasa.
MX2019002615A (es) Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion.
CO2020008887A2 (es) Inhibidores de pi4kiiiβ
MX2021013010A (es) Composiciones y metodos para modular la actividad del complemento.